Literature DB >> 11850291

In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondii.

Vanessa Yardley1, Anis A Khan, Michael B Martin, Teri R Slifer, Fausto G Araujo, Silvia N J Moreno, Roberto Docampo, Simon L Croft, Eric Oldfield.   

Abstract

The in vivo activities of three bisphosphonates were determined against Leishmania donovani and Toxoplasma gondii. Alendronate was essentially inactive against both parasites. Pamidronate was active against L. donovani by intravenous administration. Risedronate had a 50% effective dosage of five 2.6-mg/kg of body weight intraperitoneal doses against L. donovani-infected mice but was less effective against T. gondii-infected mice.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11850291      PMCID： PMC127510          DOI： 10.1128/AAC.46.3.929-931.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  6 in total

1.  A peptide prodrug approach for improving bisphosphonate oral absorption.

Authors:  A Ezra; A Hoffman; E Breuer; I S Alferiev; J Mönkkönen; N El Hanany-Rozen; G Weiss; D Stepensky; I Gati; H Cohen; S Törmälehto; G L Amidon; G Golomb
Journal:  J Med Chem       Date:  2000-10-05       Impact factor: 7.446

2.  Trypanosoma cruzi contains major pyrophosphate stores, and its growth in vitro and in vivo is blocked by pyrophosphate analogs.

Authors:  J A Urbina; B Moreno; S Vierkotter; E Oldfield; G Payares; C Sanoja; B N Bailey; W Yan; D A Scott; S N Moreno; R Docampo
Journal:  J Biol Chem       Date:  1999-11-19       Impact factor: 5.157

3.  Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase.

Authors:  A Montalvetti; B N Bailey; M B Martin; G W Severin; E Oldfield; R Docampo
Journal:  J Biol Chem       Date:  2001-07-02       Impact factor: 5.157

4.  Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy.

Authors:  M B Martin; J S Grimley; J C Lewis; H T Heath; B N Bailey; H Kendrick; V Yardley; A Caldera; R Lira; J A Urbina; S N Moreno; R Docampo; S L Croft; E Oldfield
Journal:  J Med Chem       Date:  2001-03-15       Impact factor: 7.446

5.  The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei.

Authors:  S L Croft; D Snowdon; V Yardley
Journal:  J Antimicrob Chemother       Date:  1996-12       Impact factor: 5.790

6.  The ketolide antibiotics HMR 3647 and HMR 3004 are active against Toxoplasma gondii in vitro and in murine models of infection.

Authors:  F G Araujo; A A Khan; T L Slifer; A Bryskier; J S Remington
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191
  6 in total
  29 in total

1.  Farnesyl diphosphate synthase is a cytosolic enzyme in Leishmania major promastigotes and its overexpression confers resistance to risedronate.

Authors:  Aurora Ortiz-Gómez; Carmen Jiménez; Antonio M Estévez; Juana Carrero-Lérida; Luis M Ruiz-Pérez; Dolores González-Pacanowska
Journal:  Eukaryot Cell       Date:  2006-07

2.  Farnesyl pyrophosphate synthase is essential for the promastigote and amastigote stages in Leishmania major.

Authors:  Sumit Mukherjee; Somrita Basu; Kai Zhang
Journal:  Mol Biochem Parasitol       Date:  2019-03-26       Impact factor: 1.759

3.  1-(Fluoroalkylidene)-1,1-bisphosphonic acids are potent and selective inhibitors of the enzymatic activity of Toxoplasma gondii farnesyl pyrophosphate synthase.

Authors:  Sergio H Szajnman; Valeria S Rosso; Leena Malayil; Alyssa Smith; Silvia N J Moreno; Roberto Docampo; Juan B Rodriguez
Journal:  Org Biomol Chem       Date:  2012-01-03       Impact factor: 3.876

4.  In Vitro and In Vivo Activities of Sulfur-Containing Linear Bisphosphonates against Apicomplexan Parasites.

Authors:  Sergio H Szajnman; Tamila Galaka; Zhu-Hong Li; Catherine Li; Nathan M Howell; María N Chao; Boris Striepen; Vasant Muralidharan; Silvia N J Moreno; Juan B Rodriguez
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

5.  Protective immunity using MPL-A and autoclaved Leishmania donovani as adjuvants along with a cocktail vaccine in murine model of visceral leishmaniasis.

Authors:  Tejinder Kaur; Ankita Thakur; Sukhbir Kaur
Journal:  J Parasit Dis       Date:  2012-09-06

Review 6.  Leishmaniasis treatment--a challenge that remains: a review.

Authors:  Dilvani O Santos; Carlos E R Coutinho; Maria F Madeira; Carolina G Bottino; Rodrigo T Vieira; Samara B Nascimento; Alice Bernardino; Saulo C Bourguignon; Suzana Corte-Real; Rosa T Pinho; Carlos Rangel Rodrigues; Helena C Castro
Journal:  Parasitol Res       Date:  2008-06       Impact factor: 2.289

7.  Bisphosphonate inhibition of a Plasmodium farnesyl diphosphate synthase and a general method for predicting cell-based activity from enzyme data.

Authors:  Dushyant Mukkamala; Joo Hwan No; Lauren M Cass; Ting-Kai Chang; Eric Oldfield
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

8.  Water-soluble polymer-drug conjugates for combination chemotherapy against visceral leishmaniasis.

Authors:  Salvatore Nicoletti; Karin Seifert; Ian H Gilbert
Journal:  Bioorg Med Chem       Date:  2010-03-02       Impact factor: 3.641

9.  Design, synthesis and biological evaluation of sulfur-containing 1,1-bisphosphonic acids as antiparasitic agents.

Authors:  Marion Recher; Alejandro P Barboza; Zhu-Hong Li; Melina Galizzi; Mariana Ferrer-Casal; Sergio H Szajnman; Roberto Docampo; Silvia N J Moreno; Juan B Rodriguez
Journal:  Eur J Med Chem       Date:  2012-12-20       Impact factor: 6.514

10.  Sterol Biosynthesis Pathway as Target for Anti-trypanosomatid Drugs.

Authors:  Wanderley de Souza; Juliany Cola Fernandes Rodrigues
Journal:  Interdiscip Perspect Infect Dis       Date:  2009-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.